- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02687815
Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)
Vitamin D to Prevent Severe Asthma Exacerbations
Study Overview
Detailed Description
Results from experimental studies, observational studies, two small trials, and a recent meta-analysis suggest that vitamin D reduces the risk of severe asthma exacerbations, and that this protective effect may be due to immune modulation of viral illnesses and/or increased response to inhaled corticosteroids (ICS).
On the basis of those findings, the investigators hypothesize that vitamin D reduces the incidence of severe asthma exacerbations in high-risk school-aged children who have a serum vitamin D level <30 ng/ml and who are being treated with ICS for persistent asthma. The investigators further hypothesize that this protective effect results from reduced incidence of common viral illnesses or enhanced response to ICS. These hypotheses will be tested in a 48-week randomized double-masked placebo-controlled trial of vitamin D3 supplementation to prevent severe asthma exacerbations in 400 children aged 6 to 16 years who have vitamin D insufficiency or deficiency (a serum 25(OH)D <30 ng/ml) and experienced a severe exacerbation in the prior year (a marker of high risk for subsequent events), and who (after a run-in period) are well controlled on medium-dose inhaled corticosteroids.
Our primary aim will determine whether vitamin D3 (4,000 IU/day) reduces the risk of severe asthma exacerbations (our primary outcome) in participating children. Secondary aims will determine the efficacy of vitamin D3 supplementation in: 1) preventing severe asthma exacerbations due to viral infections, 2) reducing the daily and average cumulative dose of inhaled corticosteroids.
Study participation involves 8-9 visits, with each visit lasting between 30-90 minutes. Participation requires completion of study questionnaires, spirometry (breathing tests), and collection of blood samples (to measure vitamin D levels) and urine samples (to measure urinary calcium/creatinine ratios) at some study visits. Since the start of the study, vitamin D levels and urinary calcium/creatinine ratios have been simultaneously measured, to monitor for both vitamin D toxicity and high risk of severe vitamin D deficiency or rickets, which (should they occur) would be managed by a pediatric endocrinologist or a pediatric nephrologist, as appropriate.
All safety data for the study is regularly reviewed by a Data Safety Monitoring Board appointed by the National Heart, Lung and Blood Institute, as well as by the Institutional Review Board of each participating institution. Total study participation will last about one year.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94102
- University of California - San Francisco
-
-
Colorado
-
Denver, Colorado, United States, 80206
- National Jewish Health
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Saint Louis Children's Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, United States, 44106
- Rainbow Babies and Children's Hospital
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 6 to 16 years old
- Physician-diagnosed asthma for at least one year
- At least one severe asthma exacerbation in the previous year
- Use of asthma medications (daily controller medication [ICS or leukotriene inhibitor] or inhaled β2-agonist [at least three days per week]) for at least six months in the previous year
- Vitamin D insufficiency (i.e., serum vitamin D (25(OH)D level <30 ng/ml (75 nmol/L))
- FEV1 ≥70 % of predicted
- Positive bronchodilator response (i.e., increase in FEV1 ≥8% from baseline after inhaled short acting beta agonist or increased airway responsiveness to methacholine (PC20 ≤8 mg/ml if not on ICS or PC20 ≤16 mg/ml if on ICS)
- Study protocol (i.e., age-appropriate dose of Fluticasone and no other asthma controller medications) approved by the child's regular doctor
- Parental consent and child's assent to participate in the study.
Additional inclusion criteria applied after the run-in period, to be eligible for randomization:
- Adherence with ICS and study medication (≥75% use [at least 21 of 28 days]) during the run-in period
- Willingness to be randomized and complete study
Exclusion Criteria:
- Serum calcium >10.8 mg/dl
- Serum 25(OH) D <14 ng/ml (35 nmol/L)
- Chronic respiratory disorder other than asthma
- Severe asthma (intubation for asthma at any time OR ≥3 hospitalizations for asthma in previous year OR ≥6 severe asthma exacerbations in previous year)
- Hepatic/renal disease, rickets, malabsorption, or other diseases that would affect vitamin D metabolism
- Current smoking, or former smoking if ≥5 pack-years
- Immune deficiency, cleft palate or Down's syndrome
- Treatment with anticonvulsants or ≥1,000 IU/day of vitamin D2 or D3
- Chronic oral corticosteroid therapy
- Inability to perform acceptable spirometry
- Use of investigational therapies or participation in trials 30 days before or during the study
- Participant is currently breast feeding an infant
- Pregnancy
- Weight less than 10 kg
- Plans to move out of the study site area in the next year
Additional exclusion criteria applied after the run-in period:
- Any severe asthma exacerbation during the run-in period
- Need for asthma medications other than ICS and p.r.n. rescue inhalers during the run-in period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: vitamin D3
Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
|
The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
Other Names:
|
Placebo Comparator: placebo
placebo formulations will be in gel cap form and identical to the active drug
|
The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days to a Severe Asthma Exacerbation
Time Frame: 48 weeks
|
A severe asthma exacerbation is defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR 2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids.
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days to Viral-induced Severe Exacerbation
Time Frame: 48 weeks
|
A severe viral asthma exacerbation is defined as a severe asthma exacerbation [defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR 2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids] along with a positive respiratory viral panel from a nasal blow collected within 72 hours of the exacerbation.
|
48 weeks
|
Proportion of Participants in Whom Fluticasone Dose Was Halved at Visit 6
Time Frame: 24 weeks
|
In the absence of moderate or severe asthma exacerbations, participants may have their dose of inhaled corticosteroids (ICS) reduced by 50% if the following criteria are met at visit 6 (halfway through the Trial Phase):
|
24 weeks
|
Average Cumulative Prescribed Dose of ICS at the End of the Trial
Time Frame: 48 weeks
|
The average cumulative dose of inhaled corticosteroids (ICS) during the study period
|
48 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephen Wisniewski, PhD, University of Pittsburgh
- Principal Investigator: Juan C. Celedón, MD, DrPH, University of Pittsburgh
Publications and helpful links
General Publications
- Han YY, Forno E, Bacharier LB, Phipatanakul W, Guilbert TW, Cabana MD, Ross K, Blatter J, Rosser FJ, Durrani S, Luther J, Wisniewski SR, Celedon JC. Vitamin D supplementation, lung function and asthma control in children with asthma and low vitamin D levels. Eur Respir J. 2021 Oct 28;58(4):2100989. doi: 10.1183/13993003.00989-2021. Print 2021 Oct.
- Forno E, Bacharier LB, Phipatanakul W, Guilbert TW, Cabana MD, Ross K, Covar R, Gern JE, Rosser FJ, Blatter J, Durrani S, Han YY, Wisniewski SR, Celedon JC. Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial. JAMA. 2020 Aug 25;324(8):752-760. doi: 10.1001/jama.2020.12384. Erratum In: JAMA. 2021 Jul 6;326(1):90.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- PRO12020541
- U01HL119952 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on vitamin D3 4000 IU
-
Rutgers UniversityCompleted
-
University of California, San FranciscoCompleted
-
Andrea BranchUnknownHepatocellular Carcinoma | Vitamin D DeficiencyUnited States
-
Icahn School of Medicine at Mount SinaiCompletedMetabolic Syndrome | Vitamin D Deficiency | PrediabetesUnited States
-
Brigham and Women's HospitalNational Center for Maternal and Child Health Research, Mongolia; Zuun Kharaa...CompletedVitamin D Deficiency | PregnancyMongolia
-
King Fahad Medical CityCompletedVitamin D Deficiency | Pre-Eclampsia
-
Emory UniversityChildren's Healthcare of AtlantaCompletedChronic Kidney DiseaseUnited States
-
Children's Hospital of PhiladelphiaCompleted
-
Zensun Sci. & Tech. Co., Ltd.RecruitingRecurrent Urinary Tract InfectionChina
-
Dong-A ST Co., Ltd.Unknown